Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil)

Trial Profile

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Acronyms Vaccimil
  • Most Recent Events

    • 29 Sep 2017 Planned End Date changed from 1 Nov 2015 to 31 Dec 2017.
    • 29 Sep 2017 Planned primary completion date changed from 1 Nov 2015 to 31 Dec 2017.
    • 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top